An investigation of the long-term bioactivity of endogenous growth factor in OASIS Wound Matrix.

OBJECTIVE To examine the retention and bioactivity of endogenous FGF-2 after prolonged storage within a complex matrix. FGF-2 is a growth factor found in OASIS Wound Matrix, a purified collagen wound-care product containing other endogenous components of the extracellular matrix. METHOD FGF-2 content was measured by ELISA. FGF-2 activity was measured using an in vitro bioassay in rat pheochromocytoma (PC12) cells. RESULTS FGF-2 content ranged from 15.3 ng/g to 84.3 ng/g. The bioassay showed that the FGF-2 retained in the matrix was present in a bioactive form able to cause differentiation of cells in culture. CONCLUSION The results demonstrate that wound-care products can be developed to retain their bioactivity over time and that inherently unstable purified growth factors are preserved if stored as bound factors within their natural extracellular matrix. The results also suggest that use of acellular matrices containing active growth factors would have advantages in terms of simplicity and cost over purified recombinant growth factor therapies.

[1]  C. McDevitt,et al.  Transforming growth factor-beta1 in a sterilized tissue derived from the pig small intestine submucosa. , 2003, Journal of biomedical materials research. Part A.

[2]  C. Russell Middaugh,et al.  Formulation Design of Acidic Fibroblast Growth Factor , 1993, Pharmaceutical Research.

[3]  D. Twardzik,et al.  The effect of sterilization on transforming growth factor β isolated from demineralized human bone , 1993, Transfusion.

[4]  S. Badylak,et al.  Glycosaminoglycan content of small intestinal submucosa: a bioscaffold for tissue replacement. , 1996, Tissue engineering.

[5]  R Langer,et al.  Controlled and modulated release of basic fibroblast growth factor. , 1991, Biomaterials.

[6]  R. Spence,et al.  Porcine dermal collagen as a wound dressing for skin donor sites and deep partial skin thickness burns. , 1992, Burns : journal of the International Society for Burn Injuries.

[7]  J. Smiell,et al.  Efficacy and Safely of a Topical Gel Formulation of Recombinant Human Platelet-Derived Growth Factor-BB (Becaplermin) in Patients With Chronic Neuropathic Diabetic Ulcers: A phase III randomized placebo-controlled double-blind study , 1998, Diabetes Care.

[8]  K. Nishikawa,et al.  Stabilization of fibroblast growth factors by a non-cytotoxic zwitterionic detergent, 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonate (chaps) , 1988, In Vitro Cellular & Developmental Biology.

[9]  A. Veves,et al.  A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. , 2002, Archives of surgery.

[10]  R. Baxter.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.

[11]  S. Badylak,et al.  Characterization of Fibronectin Derived from Porcine Small Intestinal Submucosa , 1998 .

[12]  B. Nies,et al.  Incorporation of basic fibroblast growth factor into methylpyrrolidinone chitosan fleeces and determination of the in vitro release characteristics. , 1994, Biomaterials.

[13]  P K Tsai,et al.  Physical stabilization of acidic fibroblast growth factor by polyanions. , 1993, Archives of biochemistry and biophysics.

[14]  L A Geddes,et al.  Small intestinal submucosa as a large diameter vascular graft in the dog. , 1989, The Journal of surgical research.

[15]  D. Ron,et al.  Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor , 1996, Cancer and Metastasis Reviews.